Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)

Therapeutic Advances in Childhood Leukemia Consortium

Status and phase: Completed; Phase 2; Phase 1

Conditions: Acute Lymphoblastic Leukemia

Treatments: Drug: PEG-asparaginase; Drug: Dexamethasone; Drug: Triple IT Therapy; Drug: Methotrexate; Drug: Doxorubicin; Drug: Bortezomib; Drug: Cytarabine; Drug: Vincristine

Study type: Interventional

Funder types: Other

Identifiers

NCT00440726

T2005-003

Details and patient eligibility

About

This is a Phase I/II study of a drug called bortezomib given in combination with chemotherapy drugs used to treat acute lymphoblastic leukemia (ALL) that has come back (recurred). Bortezomib is a drug that has been approved by the Food and Drug Administration (FDA) for treating adults with multiple myeloma which is a type of blood cancer. Bortezomib has been shown to cause cancer cells to die in studies done on animals (mice). Studies have been done that have shown that some adults and children with cancer have shown a response to bortezomib when it is used alone. Studies have also been done in adults to evaluate the dose of bortezomib that can be safely given in combination with other chemotherapy drugs.

Full description

All patients will receive 1 course of chemotherapy unless medical complications prevent the administration of some of the drugs. Treatment will last about 1 month.

Treatment on this study will consist of a combination of 7 anti-cancer medications. The 7 anti-cancer medicines are bortezomib, vincristine, dexamethasone, PEG-asparaginase, doxorubicin, cytarabine (Ara-C), and methotrexate (MTX).

If you are in the Phase I portion of this study, you will be given an assigned dose of bortezomib. The dose of bortezomib will be based on doses given in previous studies done with adults and children. At each dose level of bortezomib, between 3 and 6 children will receive bortezomib in combination with chemotherapy. If the side effects are not too severe, the next group of children will receive a higher dose. The dose will continue to be increased until we find the dose that causes serious side effects. Your dose of bortezomib will not be increased. If you have bad side effects, your dose may be decreased.

The dose used during the Phase 2 part of this study will be determined by the outcome of the Phase I study. The highest dose used in Phase I that was tolerated without serious side effects will be the one used in Phase 2.

Enrollment: 31 patients

Sex: All

Ages: 1 to 21 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

The eligibility criteria listed below are interpreted literally and cannot be waived.

1. Age Patients must be < 21 years of age when originally diagnosed with ALL. Patient must be > 1 year of age at study entry.

2. Diagnosis Patients must have relapsed or refractory ALL with a M3 marrow (marrow blasts >25%). Patients with CNS I, II or III or testicular disease are eligible.

3. Performance Level Karnofsky > 50% for patients > 10 years of age and Lansky > 50% for patients < 10 years of age.

4. Prior Therapy Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.

   1. Prior anthracycline exposure: Patients must have less than 400mg/m2 lifetime exposure of anthracycline chemotherapy.

   2. Stem Cell Transplant (SCT): Patients are eligible after allogeneic stem cell transplant as long as patients are not actively being treated for graft-versus-host-disease (GvHD).

   3. Patients should not have received previous therapy using bortezomib (Velcdade® or PS-341).

   4. During the phase I portion of the trial, there is no limit on the number of prior treatment regimens. Patients with persistent disease after an induction attempt are eligible.

   5. During the phase II portion of the trial, patients must have had two or more prior therapeutic attempts defined as:

      • Persistent initial disease after two induction attempts, or
      • Relapse after one-reinduction attempt (2nd relapse), or
      • Persistent disease after first relapse and initial re-induction attempt

      (Patients in first relapse are not eligible for the phase II portion of the study)

   6. During the phase II portion of the trial, patients must have no more than 3 prior therapeutic attempts and it must be at least 3 months since the last treatment with a "VPLD" induction/re-induction regimen.

5. Reproductive Function

   1. Female patients of childbearing potential must have a negative urine or serum pregnancy test confirmed prior to enrollment.
   2. Female patients with infants must agree not to breastfeed their infants while on this study.
   3. Male and female patients of child-bearing potential must agree to use an effective method of contraception approved by the investigator during the study.

Exclusion Criteria

1. Drug Allergies

   Patients will be excluded if they have allergies to the following:

   • Asparaginase products
   • Boron
   • Mannitol

2. Renal Function Patients will be excluded if their serum creatinine is > 2 x the upper limit of normal for age at the institution's laboratory.

3. Liver/Pancreatic Function

   1. Direct bilirubin > 1.5x the institutional ULN for age. A total bilirubin result that is less than 1.5 times the institutional ULN for age may be used for eligibility if a direct bilirubin result is not available.
   2. SGPT (ALT) > 4 x institutional ULN
   3. Grade 3 or greater pancreatitis as defined by the CTCAE v3.0
   4. History of any L-asparaginase induced pancreatitis
   5. Amylase or Lipase > 2 x institutional ULN

4. Cardiac Function Patients will be excluded if their shortening fraction by echocardiogram is less than 30%.

5. Patients with Down Syndrome are excluded.

6. Infection

   • Patients will be excluded if they have an active uncontrolled infection.
   • Patients will be excluded if they have had a positive culture within 2 weeks of study entry.

7. Patients with grade 2 or greater motor or sensory neuropathy per CTC 3.0 criteria.

8. Patients planning on receiving other investigational agents while on this study. (An investigational agent is defined as any drug not currently approved for use in humans.)

9. Patients planning on receiving other anti-cancer therapies while on this study. Hydroxyurea for cyto-reduction is allowed prior to the start of therapy.

10. Patients who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study.

11. Patients who have started protocol therapy prior to enrollment. Patient may still enroll if IT therapy was given within 72 hours of study enrollment as part of the diagnostic lumbar procedure.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Sequential Assignment

Masking: None (Open label)

---

31 participants in 2 patient groups

Ph 1 Dose Escalation

Experimental group

Description:

Intervention: Bortezomib with chemotherapy (dexamethasone, PEG-asparaginase, doxorubicin, cytarabine, methotrexate, and vincristine) and Triple IT therapy for patients who are CNS 2 or 3 at study entry. 3+3 escalation design.

Treatment:

Drug: Triple IT Therapy

Drug: Methotrexate

Drug: Vincristine

Drug: Bortezomib

Drug: Doxorubicin

Drug: Cytarabine

Drug: PEG-asparaginase

Drug: Dexamethasone

Ph 2 Efficacy and Safety

Experimental group

Description:

Intervention: Bortezomib with chemotherapy (dexamethasone, PEG-asparaginase, doxorubicin, cytarabine, methotrexate, and vincristine) and Triple IT therapy for patients who are CNS 2 or 3 at study entry. Patients receive bortezomib at maximum tolerated dose (as established in the Phase 1 portion of the study) and are assessed for response and toxicity.

Treatment:

Drug: Triple IT Therapy

Drug: Methotrexate

Drug: Vincristine

Drug: Bortezomib

Drug: Doxorubicin

Drug: Cytarabine

Drug: PEG-asparaginase

Drug: Dexamethasone